Signaturefd, LLC Xencor Inc Transaction History

Signaturefd, LLC

$4.91 Billion
Q2 2024

A detailed history of Signaturefd, LLC transactions in Xencor Inc stock. As of the latest transaction made, Signaturefd, LLC holds 1,178 shares of XNCR stock, worth $23,854. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,178

Previous 1,362 13.51%

Holding current value

$23,854

Previous $30,000 26.67%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 29, 2024	SELL	$18.21 - $24.5 $3,350 - $4,508	-184 Reduced 13.51%	1,178 $22,000
Q1 2024 May 03, 2024	SELL	$18.65 - $26.52 $1,902 - $2,705	-102 Reduced 6.97%	1,362 $30,000
Q4 2023 Jan 31, 2024	BUY	$16.53 - $21.42 $19,026 - $24,654	1,151 Added 367.73%	1,464 $31,000
Q3 2023 Nov 03, 2023	SELL	$20.08 - $25.39 $4,718 - $5,966	-235 Reduced 42.88%	313 $6,000
Q2 2023 Aug 01, 2023	BUY	$24.77 - $29.9 $5,003 - $6,039	202 Added 58.38%	548 $13,000
Q1 2023 Apr 28, 2023	SELL	$25.95 - $36.95 $1,842 - $2,623	-71 Reduced 17.03%	346 $9,000
Q4 2022 Jan 27, 2023	SELL	$24.79 - $30.86 $6,470 - $8,054	-261 Reduced 38.5%	417 $10,000
Q3 2022 Nov 08, 2022	BUY	$24.62 - $32.44 $10,734 - $14,143	436 Added 180.17%	678 $18,000
Q2 2022 Aug 10, 2022	BUY	$19.74 - $29.01 $1,006 - $1,479	51 Added 26.7%	242 $7,000
Q1 2022 May 02, 2022	BUY	$26.68 - $41.63 $186 - $291	7 Added 3.8%	191 $5,000
Q4 2021 Jan 25, 2022	BUY	$33.67 - $43.44 $3,771 - $4,865	112 Added 155.56%	184 $7,000
Q3 2021 Oct 28, 2021	BUY	$30.65 - $35.68 $2,114 - $2,461	69 Added 2300.0%	72 $2,000
Q2 2021 Jul 26, 2021	SELL	$34.33 - $44.68 $377 - $491	-11 Reduced 78.57%	3 $0
Q4 2020 Feb 11, 2021	BUY	$36.63 - $47.63 $512 - $666	14 New	14 $1,000

Others Institutions Holding XNCR

# of Institutions

204

Shares Held

63.1M

Call Options Held

3.9K

Put Options Held

View Full List

About Xencor Inc

Ticker XNCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,698,100
Market Cap $1.21B
Description
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...

More about XNCR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Signaturefd, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Signaturefd, LLC with notifications on news.

Account